Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Peter Langmuir, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Beverly Hills, California, United States
- Facility name not stated
Burbank, California, United States
- Facility name not stated
La Jolla, California, United States
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
Pomona, California, United States
- Facility name not stated
San Diego, California, United States
- Facility name not stated
New Haven, Connecticut, United States
- Facility name not stated
Fort Myers, Florida, United States
- Facility name not stated
Jacksonville, Florida, United States
- Facility name not stated
Orange City, Florida, United States
- Facility name not stated
Atlanta, Georgia, United States
- Facility name not stated
Augusta, Georgia, United States
- Facility name not stated
Chicago, Illinois, United States
- Facility name not stated
Iowa City, Iowa, United States
- Facility name not stated
Louisville, Kentucky, United States
- Facility name not stated
New Orleans, Louisiana, United States
- Facility name not stated
Baltimore, Maryland, United States
- Facility name not stated
Ann Arbor, Michigan, United States
- Facility name not stated
Southfield, Michigan, United States
- Facility name not stated
St Louis, Missouri, United States
- Facility name not stated
Hackensack, New Jersey, United States
- Facility name not stated
Morristown, New Jersey, United States
- Facility name not stated
Somerville, New Jersey, United States
- Facility name not stated
New York, New York, United States
- Facility name not stated
Durham, North Carolina, United States
- Facility name not stated
Hickory, North Carolina, United States
- Facility name not stated
Canton, Ohio, United States
- Facility name not stated
Cleveland, Ohio, United States
- Facility name not stated
Portland, Oregon, United States
- Facility name not stated
Danville, Pennsylvania, United States
- Facility name not stated
Hershey, Pennsylvania, United States
- Facility name not stated
Charleston, South Carolina, United States
- Facility name not stated
Nashville, Tennessee, United States
- Facility name not stated
Houston, Texas, United States
- Facility name not stated
San Antonio, Texas, United States
- Facility name not stated
Salt Lake City, Utah, United States
- Facility name not stated
Burlington, Vermont, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Jun 2011
- Primary completion
- 19 Dec 2018
- Completion
- 19 Dec 2018
- Last update posted
- 28 Jan 2020
- Registered enrollment
- 66
- Registry id
- NCT01348490
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.